Could rerouting the gut and cutting nerves free people from diabetes drugs?
NCT ID NCT02949687
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This trial investigates a surgical procedure for people with type 2 diabetes and mild obesity (grade 1). The surgery combines three steps: rerouting part of the small intestine, reducing the stomach size, and cutting certain abdominal nerves. The goal is to see if this approach can bring blood sugar levels to normal without the need for diabetes medications. The study follows participants for 24 months to measure success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- laparoscopic ileal interposition with sleeve and sympathectomy
- What this could lead to
- If successful, this surgery could allow some people with type 2 diabetes and mild obesity to stop taking diabetes medications while maintaining normal blood sugar levels.
- What could go wrong
- This is a small, early-stage surgical trial with no control group, so results may not apply widely. Surgery carries risks like infection, bleeding, and long-term digestive changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Quitting smoking may also ward off diabetes — a trial puts the dual strategy to the test
- Could a simple clinic Check-In change catch hidden high blood pressure and diabetes?
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?